Beam Therapeutics Inc. [—] Shares of Common Stock Underwriting AgreementBeam Therapeutics Inc. • January 27th, 2020 • Biological products, (no disgnostic substances) • New York
Beam Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $[•] per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
BEAM THERAPEUTICS INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a stock option granted by Beam Therapeutics Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Beam Therapeutics Inc. 2019 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
Beam Therapeutics Inc.Letter Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This amended and restated letter agreement (this “Agreement”) confirms the terms and conditions of your employment as the Chief Executive Officer of Beam Therapeutics Inc. (the “Company”), working out of the Company’s headquarters located in Cambridge, Massachusetts, effective as of the day prior to the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended (the “Effective Date”).
BEAM THERAPEUTICS INC. NON-STATUTORY STOCK OPTION AGREEMENT (NON-EMPLOYEE DIRECTORS)Stock Option Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a stock option granted by Beam Therapeutics Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Beam Therapeutics Inc. 2019 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
BEAM THERAPEUTICS INC. NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a stock option granted by Beam Therapeutics Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Beam Therapeutics Inc. 2019 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
Beam Therapeutics Inc.Letter Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter agreement (this “Agreement”) confirms the terms and conditions of your employment with Beam Therapeutics Inc. (the “Company”), effective as of the day prior to the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended (the “Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 27th, 2020 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of January 24, 2020 by and between Beam Therapeutics Inc. (the “Company”) and Giuseppe (“Pino”) Ciaramella (the “Executive”), and is effective as of the day prior to the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended (the “Effective Date”).
